CENTER ON BEHAVIORAL MEDICINE

BODY-MIND CONNECTION

ESSENTIAL NUTRIENTS

Essential Nutrients-Cognition:  Research Article

Essential Nutrients Menu

B vitamins, Homocysteine, and Neurocognitive Function in the
Elderly


CITATION:  Selhub, J., Bagley, L.C., et al.  (2000)  B vitamins, Homocysteine, and Neurocognitive Function in the Elderly.  Am J Clin Nutr 2000;71(suppl):614S–20S.

ABSTRACT: 
Evidence of the importance of the B vitamins folic acid, vitamin B-12, and vitamin B-6 for the well-being and normal function of the brain derives from data showing neurologic and psychologic dysfunction in vitamin deficiency states and in cases of congenital defects of one-carbon metabolism. The status of these vitamins is frequently inadequate in the elderly and recent studies have shown associations between loss of cognitive function or Alzheimer disease and inadequate B vitamin status. The question that arises is whether these B vitamin inadequacies contribute to such brain malfunctions or result from aging and disease. From a theoretical standpoint, these inadequacies could give rise to impairment of methylation reactions that are crucial to the health of brain tissue. In addition or perhaps instead, these inadequacies could result in hyperhomocysteinemia, a recently identified risk factor for occlusive vascular disease, stroke, and thrombosis, any of which may result in brain ischemia. Advances in the understanding of this putative relation between inadequate vitamin status and loss of cognitive function in the elderly are likely to be slow and may depend on the outcomes of both prospective studies and longitudinal studies in which nutritional intervention is provided before cognitive decline occurs.

References

1. Morley JE, Levine AS, Yim GK, Lowy MT. Opioid modulation of appetite. Neurosci Biobehav Rev 1983;7:281–305.

2. Schiffman SS, Hornack K, Reilly D. Increased taste thresholds of amino acids with age. Am J Clin Nutr 1979;32:1622–7.

3. Parnetti L, Bottiglieri T, Lowenthal D. Role of homocysteine in agerelated
vascular and non-vascular diseases. Aging (Milano) 1997; 9:241–57.

4. Bottiglieri T. Folate, vitamin B12, and neuropsychiatric disorders. Nutr Rev 1996;54:382–90.

5. Bottiglieri T, Crellin RF, Reynolds EH. Folates and neuropschiatry. In: Bailey L, ed. Folate in health and disease. New York: Marcel Dekker, 1994:435–62.

6. Nourhashémi F, Gillette-Guyonnet S, Andrieu S, et al. Alzheimer disease: protective factors. Am J Clin Nutr 2000;71(suppl):643S–9S.

7. Krasinski SD, Russell RM, Samloff IM, et al. Fundic atrophic gastritis in an elderly population: effect on hemoglobin and several serum nutritional indicators. J Am Geriatr Soc 1986;34:800–6.

8. Russell RM, Krasinski SD, Samloff IM, Jacob RA, Hartz SC, Brovender SR. Folic acid malabsorption in atrophic gastritis. Possible compensation by bacterial folate synthesis. Gastroenterology 1986;91:1476–82.

9. Russell RM, Dhar GJ, Dutta SK, Rosenberg IH. Influence of intraluminal pH on folate absorption: studies in control subjects and in patients with pancreatic insufficiency. J Lab Clin Med 1979;93:428–36.

10. Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin
status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–8.

11. Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 1983;249:2917–21.

12. Karnaze DS, Carmel R. Low serum cobalamin levels in primary degenerative dementia. Arch Intern Med 1987;147:429–31.

13. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720–8.

14. Renvall MJ, Spindler AA, Ramsdell JW, Paskvan M. Nutritional status of free-living Alzheimer’s patients. Am J Med Sci 1989;298:20–7.

15. Tucker DM, Penland JG, Sandstead HH, Milne DB, Heck DG, Klevay LM. Nutrition status and brain function in aging. Am J Clin Nutr 1990;52:93–102.

16. Nijst TQ, Wevers RA, Schoonderwaldt HC, Hommes OR, Haan AFJ. Vitamin B12 and folate concentrations in serum and cerbrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia. J Neurol Neurosurg Psychiatry 1990;53:951–4.

17. Bell IR, Edman JS, Selhub J, et al. Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr Scand 1992;86:386–90.

18. Levitt AJ, Karlinsky H. Folate, vitamin B12 and cognitive impairment in patients with Alzheimer’s disease. Acta Psychiatr Scand 1992;86:301–5.

19. Kristensen MO, Gulmann NC, Christensen JEJ, Ostergaard K, Rasmussen
K. Serum cobalamin and methylmalonic acid in Alzheimer dementia. Acta Neurol Scand 1993;87:475–81.

20. Crystal HA, Ortof E, Frishman WH, Gruber A, Hershman D, Aronson M. Vitamin B12 levels and incidence of dementia in a healthy elderly population: a report from the Bronx Longitudinal Aging Study. J Am Geriatr Soc 1994;42:933–6.

21. Nilsson K, Gustafson L, Faldt R, et al. Hyperhomocysteinaemia—a common finding in psychogeriatric population. Eur J Clin Invest 1996;26:853–9.

22. Ortega RM, Manas LR, Andres P, et al. Functional and psychic deterioration
in elderly people may be aggravated by folate deficiency. J Nutr 1996;126:1992–6.

23. Dror Y, Stern F, Nemesh L, Hart J, Grinblat J. Estimation of vitamin
needsóriboflavin, vitamin B-6 and ascorbic acidóaccording to blood parameters and functional, cognitive and emotional indices in a selected well-established group of elderly in a home for the aged in Israel. J Am Coll Nutr 1996;15:481–8.

24. Riggs KM, Spiro A III, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996; 63:306–14.

25. La Rue A, Koehler KM, Wayne SJ, Chiulli SJ, Haaland KY, Garry PJ. Nutritional status and cognitive functioning in a normally aging sample: a 6-y reassessment. Am J Clin Nutr 1997; 65:20–9.

26. Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin B12 and folate deficiency more frequent in elderly patients with Alzheimer’s disease? J Gerontol A Biol Sci Med Sci 1997;52:M76–9.

27. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12 and serum total homocysteine in confirmed Alzheimer’s disease. Arch Neurol 1998;55:1449–55.

28. D’Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90:1–11.

29. Bellamy MF, McDowell IF. Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis 1997;20:307–15.

30. Deifen JB, Beek EJ, Orlebeke JF, Berg H. Vitamin B-6 supplementation in elderly men: effects on mood, memory, performance and mental effort. Psychopharmacology 1992;109:489–96.

31. Martin DC, Francis J, Protetch J, Huff FJ. Time dependency of cognitive
recovery with cobalamin replacement: report of a pilot study. J Am Geriatr Soc 1992;40:168–72.

32. Strittmatter WJ, Gagnon C, Axelrod J. Beta adrenergic stimulation of protein carboxymethylation and amylase secretion in rat parotid gland. J Pharmacol Exp Ther 1978;207:419–24.

33. Axelrod J. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol Rev 1966;18:95–113.

34. Flynn DD, Kloog Y, Potter LT, Axelrod J. Enzymatic methylation of the membrane-bound nicotinic acetylcholine receptor. J Biol Chem 1982;257:9513–7.

35. Axelrod J, Hirata F. Phospholipid methylation and membrane function.
Ann N Y Acad Sci 1981;373:51–3.

36. Enk D, Hougaard K, Hippe E. Reversible dementia and neuropathy
associated with folate deficiency 16 years after partial gastrectomy. Scand J Haematol 1980;25:63–6.

37. Rosenberg IH, Miller JW. Nutritional factors in physical and cognitive functions of elderly people. Am J Clin Nutr 1992;55:1237S–43S.

38. Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders.
Drugs. 1993;45:623–36.

39. Weir DG, Keating S, Molloy A, et al. Methylation deficiency causes
vitamin B12 associated neuropathy in the pig. J Neurochem 1988; 51:1949–52.

40. Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (Sadenosylmethionine) in neurological disorders. Drugs 1994;48:137–52.

41. Agnoli A, Andreoli VM, Casacchia M, Maffei F, Fazio C. Result and
possible developments of the clinical use of S-adenosyl-L-methionine (SAMe) in psychiatry. Monogr Gesamtgeb Psychiatr Psychiatry Ser 1978;18:170–82.

42. Lipinski JF, Cohen BM, Frankenberg F, et al. Open trial of -adenosylmethionine
for treatment of depression. Am J Psychiatry 1984;141:448–50.

43. Carney MWP, Toone BK, Reynolds EH. S-adenosylmethionine and affective disorder. Am J Med 1987;83:104–6.

44. Rosenbaum JF, Fava M, Falk WE, et al. An open-label pilot study of oral S-adenosyl-l-methionine in major depression: interim results. Psychopharmacol Bull 1988;24:189–94.

45. Janicak PG, Lipinski J, Davis JM, et al. S-adenosylmethionine in depression. A literature review and preliminary report. Ala J Med Sci 1988;25:306–13.

46. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: metaanalysis
of clinical studies. Acta Neurol Scand Suppl 1994;154:7–14.

47. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992;55:131–8.

48. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative
assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049–57.